Women & HIV
Women & HIV
CROI 2012: Hormonal Contraception May Raise HIV Risk for Women, but Uncertainty Remains
- Details
- Category: HIV Sexual Transmission
- Published on Wednesday, 07 March 2012 00:00
- Written by Keith Alcorn
Injectable hormonal contraception may raise the risk of HIV infection for women, but it does not appear to increase the risk of HIV disease progression in women with HIV, according to findings from 2 new studies presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this week in Seattle.
WHO Affirms That Women at Risk for HIV Should Continue To Use Injectable Contraceptives
- Details
- Category: HIV Sexual Transmission
- Published on Friday, 02 March 2012 00:00
- Written by Liz Highleyman
The World Health Organization (WHO) has affirmed its 2009 policy that women living with or at risk for HIV should continue to use hormonal contraception, despite conflicting results from recent studies suggesting that oral or injectable hormones may increase the risk of HIV infection.
EACS 2011: Do Women with HIV Experience Earlier Menopause?
- Details
- Category: Women & HIV
- Published on Thursday, 13 October 2011 00:00
- Written by Liz Highleyman
Premature menopause may be more common among women with HIV, but the difference is primarily driven by women with advanced immune deficiency, according to study results presented at the 13th European AIDS Conference (EACS 2011) this week in Belgrade.
Pets and Parenthood Help Women Cope with HIV
- Details
- Category: Women & HIV
- Published on Friday, 27 January 2012 00:00
- Written by Liz Highleyman
Identification with their role as a mother, grandmother, or pet owner helped women with HIV cope with having a chronic disease, according to a study published in the January 2012 online edition of Women's Health Issues.
Quad Pill Works as Well as Atazanavir Combo at 48 Weeks
- Details
- Category: HIV Treatment
- Published on Friday, 23 September 2011 00:00
- Written by Gilead Sciences
The experimental Quad pill -- a once-daily single-tablet regimen containing the integrase inhibitor elvitegravir, the novel boosting agent cobicistat, and the NRTIs tenofovir and emtricitabine -- met a 48-week primary endpoint demonstrating non-inferiority to a boosted atazanavir regimen, Gilead Sciences announced this week. Both combinations suppressed HIV RNA in about 90% of treatment-naive HIV patients, but fewer people discontinued the Quad due to side effects. 
More Articles...
- ICAAC 2011: Cobicistat Matches Ritonavir as Booster, Studies Clarify Effects on Kidney Function
- ICAAC 2011: Raltegravir is Effective and Well-tolerated in Diverse Populations with HIV
- CDC Fact Sheets on HIV among Women and Transgender People
- IAS 2011: Hormonal Contraceptive Use Increases Women’s Risk of Acquiring and Transmitting HIV
Web Design and Development by